Intestinal bacteria and inflammatory bowel disease

Critical Reviews in Clinical Laboratory Sciences

Volumn 46, Issue 1, 2009, Pages 25-54

  Macfarlane, Sandra ^a,b   Steed, Helen ^a   Macfarlane, George T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Antibiotics; Colon; Crohn's disease; Microbiota; Mucosal bacteria; Mycobacteria; Prebiotics; Probiotics; Sulfate reducing bacteria; Synbiotics; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; ORNIDAZOLE; PLACEBO; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RIFABUTIN; RIFAMPICIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; STEROID; SULFAPYRIDINE; UNINDEXED DRUG; VANCOMYCIN;

ADRENAL SUPPRESSION; AGRANULOCYTOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; CONTINUOUS INFUSION; CROHN DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; ENTERITIS; ESCHERICHIA COLI; FEVER; FOLIC ACID DEFICIENCY; HELICOBACTER INFECTION; HEPATITIS; HUMAN; INFERTILITY; INTESTINE FLORA; INTESTINE SURGERY; LEUKOPENIA; LYMPHOMA; MICROBIAL COMMUNITY; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN CANCER; SULFATE REDUCING BACTERIUM; SYSTEMIC DISEASE; TOTAL PARENTERAL NUTRITION; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; VOMITING;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MYCOBACTERIUM; PROBIOTICS; SULFIDES;

ANIMALIA; BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE;

EID: 58149132307     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360802485792     Document Type: Review

References (275)

1. Macfarlane S, Hopkins MJ, Macfarlane GT. Bacterial growth and metabolism on surfaces in the large intestine. Microb Ecol Health Dis 2000; 2: 64-72.
2. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107-133.
3. Macfarlane GT, Gibson GR, Drasar BS, Cummings JH. Metabolic significance of the colonic microflora. In Whitehead R, Ed. Gastrointestinal and Oesophageal Physiology. Pp 249-274. Edinburgh: Churchill Livingstone, 1995.
4. Macfarlane GT, Gibson GR. Metabolic activities of the normal colonic flora. In Gibson SAW, Ed. Human Health: The Contribution of Microorganisms. Pp 17-52. London: Springer Verlag, 1994.
5. Sharp R, Ziemer CJ. Application of taxonomy and systematics to molecular techniques in intestinalmicrobiology. In Gibson GR, Roberfroid M, Eds. Colonic Microflora, Nutrition and Health. Pp 167-190. London: Chapman and Hall, 1999.
6. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease-related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance and community cellular fatty acid profiles. Gut 2001; 48: 198-205.
7. McBain AJ, Macfarlane GT. Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites. J Med Microbiol 1998; 47: 407-416.
8. Macfarlane GT, Macfarlane S. Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. In Isolauri I, Walker WA, Eds. Allergic Diseases and the Environment. Pp 179-198. Basel: Vevey/S. Karger AG, 2004
9. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-459.
10. Finegold SM, Sutter VL, Mathisen GE. Normal indigenous intestinal flora. In Hentges DJ, Ed. Human intestinal microflora in health and disease. Pp 3-31. London: Academic Press, 1983.
11. Woodmansey EJ, McMurdo MET, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic treated elderly subjects. Appl Environ Microbiol 2004: 70: 6113-6122.
12. Bartosch S, Fite A, Macfarlane GT, McMurdo MET. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients using real-time PCR and the effects of antibiotic treatment on the fecal microflora. Appl Environ Microbiol 2004; 70: 3575-3581.
13. Cummings JH, Macfarlane GT, Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr Iss Intest Microbiol 2003; 4: 9-20.
14. Sands BE. From symptoms to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2002; 126: 1518-1532.
15. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
16. Loftus Ev Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 2004; 126: 1504-1517.
17. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14: 1553-1559.
18. Bergman L, Krause U. The incidence of Crohn's disease in central Sweden. Scand J Gastroenterol 1975; 10: 725-729.
19. Mayberry JF, Probert CSJ, Jayanthi V, Shivananda S. Epidemiology of inflammatory bowel disease: a European perspective. In Anagnostides AA, Hodgson HJF, Kirsner JB, Eds. Inflammatory Bowel Disease. Pp 163-178. London: Chapman and Hall, 1991.
20. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between the north and south? Results of the European collaborative study on inflammatory bowel disease. Gut 1996; 39: 690-697.
21. Falla-Alvarez L, Albacete R. Further experience with chronic regional enteritis in Cuba. S Med J 1958; 51: 1556-1561.
22. Hutt MSR. Epidemiology of chronic intestinal disease in Middle Africa. Israel J Med Sci 1979; 15: 314-317.
23. Tysk C, Lindberg E, Jarnerot G, Floderus-My-Led B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of inheritability and the influence of smoking. Gut 1988; 29: 990.
24. Wetterman IT, Pena AS. Familial incidence of Crohn's disease in the Netherlands and a review of the literature. Gastroenterology 1984; 86: 449-452.
25. Lewkonia RM, McConnell RB. Familial inflammatory bowel disease-hereditary or environment? Gut 1976; 17: 235-243.
26. Begleiter ML, Harris DJ. Familial incidence of Crohn's disease. Gastroenterology 1985; 88: 221.
27. Orholm M, Nlunkholm P, Langholz E, Haaen Nielsen O, Borensen TS, Binder V. Familial occurrence of inflammatory bowel disease. N Eng J Med 1991; 324: 84.
28. Thornton JR, Emmett PM, Heaton KW. Diet and Crohn's disease: characteristics of the pre-illness diet. Br Med J 1979; 2: 762-764.
29. Gilat T, Hacohen D, Lilos P, Langman MJS. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009-1024.
30. Rozen P, Zonis J, Yekutiel P, Gilat T. Crohn's disease in the Jewish population of Tel-Aviv-Yafo. Gastroenterology 1979; 76: 25-30.
31. Dickinson RJ, Ashton MG, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjuvant to the routine therapy of acute colitis. Gastroenterology 1980; 79: 1199-1204.
32. Sartor RB. Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 1990; 4: 271-277.
33. Sartor RB. Enteric microflora in inflammatory bowel disease: pathogens or commensals? Inflamm Bowel Dis 1997; 3: 23-35.
34. Prantera C, Scribang ML, Berto E, Zannoni F. Antibiotic use in Crohn's disease. Why and How? Bio Drugs 1997; 8: 293-306.
35. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
36. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006; 36: 668-678.
37. O'Neil DA. Regulation of expression of beta-defensins: endogenous enteric peptide antibiotics. Mol Immunol 2003; 40: 445-450.
38. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JWD, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. Lack of effect of intravenous administration on time to respond to azathioprine for steroid treated Crohn's disease. Gastroenterology 1999; 117: 527-535.
39. Fais S, Pallone F, Squarcia O, Boirivant M, Pozzilli P. T cell early activation antigens expressed by peripheral lymphocytes in Crohn's disease. J Lab Clin Med 1985; 16: 75-76.
40. Mueller C, Knoflach P, Zienlinski CC. T cell activation in Crohn's disease: increased levels of soluble interleukin 2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology 1990; 98: 639-646.
41. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells frompatients with inflammatory bowel disease. J Clin Invest 1990; 86: 1255-1260.
42. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binon DG, Musso A, West GA, Dobrea GM, McCormick TS, Lapetina EG, Levine AD, Ottaway CA, Fiocchi C. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with Bcl-2/Bax mucosal imbalance. J Immunol 1999; 163: 1081-1090.
43. Boirvant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway induced apoptosis. Gastroenterology 1999; 116: 557-565.
44. Binon DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997; 112: 1895-1907.
45. Teahon K, Bjarnason I, Person M, Levi AJ. Ten years experience with an elemental diet in the management of Crohn's disease. Gut 1990; 31: 1133.
46. Hanauer SB, Strömberg U. Oral pentasa in the treatment of active Crohn's disease: a meta analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 379-388.
47. Rutgeerts P, Lofberg R, Malchow, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, Hodgson H, Persson T, Seidegard C. A comparison of Budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-845.
48. Otley A, Steinhart AH, Otley A. Budesonide for induction of remission in Crohn's disease. Cochrane Library. Issue 4 Chichester: Wiley, 2005.
49. Pearson DC, May GR, Fick GR, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Library Issue 2 Oxford: Update Software, 2000.
50. Fraser AG. Methotrexate: first or second line immunomodulator? Eur J Gastroenterol Hepatol 2003; 15: 225-231.
51. Targan SR, Hanaeur SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short term study of chimeric monoclonal antibody cA2 to TNF alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-1035.
52. Ljung T, Karlen P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-853.
53. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
54. Carter MJ, Lobo AJ, Travis SPL on behalf of the IBD section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: v1-v16.
55. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963.
56. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut 1992; 33: 331-335.
57. Magee EA, Edmond LM, Tasker SM, Kong SC, Curno R, Cummings JH. Associations between diet and disease activity in ulcerative colitis patients using a novel method of data analysis. Nutr J 2005; 4: 7.
58. Chin AC, Parkos CA. Neutrophil transepithelial migration and epithelial barrier function in IBD: potential targets for inhibiting neutrophil trafficking. Ann N Y Acad Sci 2006; 1072: 276-287.
59. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4 lamina propria lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-1270.
60. Nash S, Stafford J, Madara JL. Effects of polymorphonuclear leukocyte transmigration on the barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1987; 80: 1104-1113.
61. Loftus EV, Kane SV, Bjorkman D. Systemic review: short term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 179-189.
62. Hawthorne AB. Cyclosporin and refractory colitis. Eur J Gastroeneterol Hepatol 2003; 15: 239-244.
63. Sandborn W, McLeod R, Jewell DP. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev 2001: CD001176.
64. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007; 25: 1055-1060.
65. Victor RJ, Kirsner JB, Palmer W. Failure to induce ulcerative colitis experimentally with filtrates of feces and rectal mucosa. Gastroenterology 1950; 14: 398.
66. Rietschel ET, Kirkae T, Schade FU, Mamat U, Schmidt G, Loppnow H, Ulmer AJ, Zahringer U, Sevdel U, Di Padova F, Schreier M, Brade H. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8: 217-225.
67. Oriishi T, Sata M, Toyonaga A, Sasaki E, Tanikawa K. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut 1995; 36: 891-896.
68. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, Rowlands BJ. Significance of systemic endotoxaemia ininflammatory bowel disease. Gut 1995; 36: 897-901.
69. Eade MN, Brooke BN. Portal bacteraemia in cases of ulcerative colitis submitted to colectomy. Lancet 1969; 1: 1008-1009.
70. Van Kruningen HJ, Colombel JF, Cartun RW, Whitlock RH, Koopmans M, Kangro HO, Hoogkamp-Korstanje JA, Lecomte-Houcke M, Devred M, Paris JC, Cortot A. An in-depth study of Crohn's disease in two French families. Gastroenterology 1993; 104: 351-360.
71. Munro J, Mayberry J, Matthews N, Rhodes J. Chlamydia and Crohn's disease. Lancet 1979; 2: 45-46.
72. Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2: 693-696.
73. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. Immunocytochemical evidence of Listeria, Escherichia coli and streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108: 1396-1404.
74. I Roediger WE, Macfarlane GT. A role for intestinal mycoplasma in the aetiology of Crohn's disease? J Appl Microbiol 2002; 92: 377-381.
75. Gassull MA, Fernández-Bañares F, Cabré E, Papo M, Giaffer MH, Sánchez-Lombraña JL, Richart C, Malchow H, González-Huix F, Esteve M. European Group on Enteral Nutrition in Crohn's Disease. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut 2002; 51(2): 164-168.
76. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin and azithromycin. Mayo Clinic Proc 1999; 74: 613-634.
77. Rubin PH, Chapman ML, Scherl E, Sachar DB, Stamaty C, Present DH. Clarithromycin in active Crohn's disease (CD): preliminary results of an open label pilot study. Gastroenterology 1996; 110; A1005.
78. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Therap 2000; 14: 801-806.
79. Gui GPH, Thomas PRS, Tizard MLV, Lake J, Sanderson JD, Hermon-Taylor J. Two year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 1997; 39: 393-400.
80. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease (CD) using antimycobacterial triple therapy-approaching a cure? Digest Liver Dis 2002; 34: 29-38.
81. Bamba T, Matsuda H, Endo M, Fujiyama Y. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J Gastroenterol 1995; 30: 45-47.
82. Belsheim M, Darwisk R, Watson M. Bacterial L-form isolation from inflammatory bowel disease patients. Gastroenterology 1983; 85: 364-369.
83. Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet 1996; 347: 40-44.
84. Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Salas A, Forcada P, Laguarda M, Gavaldá J, Baena JA, Vilaseca J, Malagelada JR. Incrimination of anaerobic bacteria in the induction of experimental colitis. Am J Physiol 1997; 272: G10-15.
85. Mourelle M, Salas A, Guarner F, Crespo E, García-Lafuente A, Malagelada JR. Stimulation of transforming growth factor-beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998; 114: 519-526.
86. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
87. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut 2004; 53: 1-4.
88. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Dore J. Alterations of the dominant fecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242.
89. Van de Merwe JP, Schroder AM, Wensinck F, Hazenberg MP. The obligate anaerobic faecal flora of patients with Crohn's disease and their first degree relatives. Scand J Gastroenterol 1988; 23: 1125-1131.
90. Giaffer MH, Holdsworth CD, Duerde BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991; 35: 238-243.
91. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal mirobiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55; 205-211.
92. Comes MC, Gower-Rousseau C, Colombel JF, Belaiche J, Van Kruiningen HJ, Nuttens MC, Cortot A. Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Leige county of Belgium. Gut 1994; 35: 1316-1318.
93. Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large population based epidemiologic study. Gastroenterology 1991; 100: 350-358.
94. Kotiowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007; 56: 669-675.
95. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004; 127: 80-93.
96. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich C, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
97. Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. Gut-associated bacterial microbiota in paedatric patients with inflammatory bowel disease. Gut 2006; 55: 1760-1767.
98. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular characterisation of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 481-487.
99. Burke D, Axon A. Adhesive E. coli in inflammatory bowel disease and infective diarrhoea. Br Med J 1988; 297: 102-104.
100. Chadwick VS. Etiology of chronic ulcerative colitis and Crohn's disease. In Philips SF, Pemberton JH, Shorter RG, Eds. The Large Intestine: Physiology, Pathophysiology and Disease. Pp. 445-463. New York: Raven Press Ltd, 1991.
101. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992; 33: 646-650.
102. Hartley MG, Hudson MJ, Swarbrick ET, Gent AE, Hellier MD, Grace RH. Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis. Gut 1993; 34: 63-67.
103. Schultsz C, Moussa M, van Ketel R, Tytgat GN, Dankert J. Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls. J Clin Pathol 1997; 50: 573-579.
104. Walmsley RS, Anthony A, Sim R, Pounder RE, Wakefield AJ. Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol 1998; 51: 657-661.
105. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, DiMartino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405-1413.
106. Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease Curr Opin Infect Dis 2006; 19: 475-484.
107. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Imuun 2000; 68: 1542-1548.
108. Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun 1997; 10: 175-180.
109. Rolhion N, Darfeuille-Michaud A. Adherent-invasive (Escherichia coli) in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1277-1283.
110. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69: 5529-5537.
111. Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest 2007; 87: 1042-1054.
112. Subramanian S, Rhodes JM, Hart CA, Tam B, Roberts CL, Smith SL, Corkhill JE, Winstanley C, Virji M, Campbell BJ. Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis 2008; 14: 162-175.
113. Dalziel TK. Chronic intestinal enteritis. Br Med J 1913; 2: 1068-1070.
114. Greenstein RJ. Is Crohn's Disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis and Johne's disease. Lancet Infect Dis 2003; 3: 507-514.
115. Johne HA, Frothengham I. Ein iegenthumilicher fail von tuberculose beim rind (A peculiar case of tuberculosis in a cow) Deutsche Zeitschr Tierm 1895; 21: 438-454.
116. Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, Zanetti S, Hermon-Taylor J. Mycobacterium avium subspecies paratuberculosis infection in irritable bowel syndrome and comparison with Crohn's and Johne's diseases: common neural and immune pathogenicities. J Clin Microbiol 2007; 45: 3883-3890.
117. Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004; 364: 1039-1044.
118. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA. Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. J Clin Microbiol 1986; 24: 357-363.
119. Haagsma J, Mulder CJJ, Eger A, Bruins J, Ketel RJ, Tytgat GNJ. Mycobacterium species isolated from patients with Crohn's disease. In MacDermott RP, Ed. Inflammatory Bowel Disease. Current Status and Future Approach. Pp. 535-538. Amsterdam-New York-Oxford: Excerpta Medica, 1988.
120. Sechi LA, Scanu AM, Molicotti P, Cannas S, Mura M, Dettori G, Fadda G, Zanetti S. Detection and isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia Am J Gastroenterol 2005; 100: 1529-1536.
121. Elsaghier A, Prantera C, Moreno C, Ivanyi J. Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease. Clin Exp Immunol 1992; 90: 503-508.
122. Naser S, Shafran I, El-Zaatari F. Mycobacterium avium subspecies paratuberculosis in Crohn's disease is serologically positive. Clin Diagn Lab Immunol 1999; 6: 282.
123. Abubakar I, Myhill D, Aliyu SH, Hunter PR. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques. A systematic review and meta-analysis. Inflamm Bowel Dis 2008; 14: 401-410.
124. Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Pfyffer GE, Jemmi T, Baumgartner A, Egger M. Mycobacterium avium subspecies tuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 607-613.
125. Hulten K, El-Zimaity HM, Karttunen TJ, Almashhrawi A, Schwartz MR, Graham DY, El-Zaatari FA. Detection of Mycobacterium avium subsp. paratuberculosis in Crohn's diseased tissues by in situ hybridization. Am J Gastroenterol 2001; 96: 1529-1535.
126. Dell'Isola B, Poyart C, Goulet O, Mougenot JF, Sadoun-Journo E, Brousse N, Schmitz J, Ricour C, Berche P. Detection of Mycobacterium paratuberculosis by polymerase chain reaction in children with Crohn's disease. J Infect Dis 1994; 169: 449-451.
127. Lisby G, Andersen J, Engbaek K, Binder V. Mycobacterium paratuberculosis in intestinal tissue from patients with Crohn's disease demonstrated by a nested primer polymerase chain reaction. Scand J Gastroenterol 1994; 29: 923-929.
128. Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR Jr, Coutu JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J Clin Microbiol 1984; 20: 966-971.
129. Stanford JL, Dourmashkin R, McIntyre G, Visuvanathan S. Do mycobacteria exist in alternative physical forms and what part do they play in the etiology of inflammatory bowel disease? In MacDermott RP, Ed. Inflammatory Bowel Diseases: Current Status and Future Approaches. Pp 503-508. Amsterdam: Elsevier Science, 1988.
130. Markesich DC, Graham DY, Yoshimura HH. Progress in culture and subculture of spheroplasts and fastidious acid fast bacilli isolated from intestinal tissues. J Clin Microbiol 1988; 26: 1600-1603.
131. Gitnick G, Collins J, Beaman B, Brooks D, Arthur M, Imaeda T, Palieschesky M. Preliminary report on isolation of mycobacteria from patients with Crohn's disease. Dig Dis Sci 1989; 34: 925-932.
132. Green EP, Tizard MLV, Moss MT, Thompson J, Winterbourne DJ, McFadden JJ, Hermon-Taylor J. Sequence and characteristics of IS900, an insertion identified in a human Crohn's disease isolate of Mycobacterium paratuberculosis. Nucleic Acid Res 1989; 17: 9063-9073.
133. Kunze ZM, Wall S, Appelberg R, Silva MT, Portaels F, McFadden JJ. IS901, a new member of a widespread class of atypical insertion sequences is associated with pathogenicity in Mycobacterium avium. Mol Microbiol 1991; 5: 2265-2272.
134. Hermon-Taylor J, Bull TJ, Sheridan JM, Cheng J, Stellakis ML, Sumar N. Causation of Crohn's disease by Mycobacterium avium subspecies paratuberculosis. Can J Gastroenterol 2000; 14: 521-539.
135. Jeyanathan M, Alexander DC, Turenne CY, Girard C, Behr MA. Evaluation of in situ methods used to detect Mycobacterium avium subsp. paratuberculosis in samples from patients with Crohn's Disease. J Clin Microbiol 2006; 44: 2942-2950.
136. Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 1992; 33: 890-896.
137. Cousins DV, Whittington R, Marsh I, Masters A, Evans RJ, Kluver P. Mycobacteria distinct from Mycobacterium avium subsp. paratuberculosis isolated from the faeces of ruminants possess IS900-like sequences detectable by IS900 polymerase chain reaction: implications for diagnosis. Mol Cell Probes 1999; 13: 431-442.
138. Englund S, Bolske G, Johansson KE. An IS900-like sequence found in a Mycobacterium sp. other than Mycobacterium avium subsp. paratuberculosis. FEMS Microbiol Lett 2002; 209: 267-271.
139. Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G, Pickup R, Hermon-Taylor J. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol 2003; 41: 2915-2923.
140. Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, Holby N, Harms BA, Thomsen OO, Skibsted U, Binder V. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol 2000; 38: 4373-4381.
141. Schwartz D, Shafran I, Romero C, Piromalli C, Biggerstaff J, Naser N, Chamberlin W, Naser SA. Use of short-term culture for identification of Mycobacterium avium subsp. paratuberculosis in tissue from Crohn's disease patients. Clin Microbiol Inf 2000; 6: 303-307.
142. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-734.
143. Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. J Clin Microbial 2004; 42: 1129-1135.
144. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duer RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
145. Sechi LA, Gazouli M, Ikonomopolous JC, Lukas JC, Scanu AM, Ahmed N, Fadda G, Zanetti S. Mycobacterium avium subsp. paratuberculosis, genetic susceptibility to Crohn's disease, and Sardinians: the way ahead. J Clin Microbiol 2005; 43: 5275-5277.
146. Ferwerda G, Kullberg BJ, de Jong DJ, Girardin SE, Langenberg DM, van Crevel R, Ottenhoff TH, Van der Meer JW, Netea MG. Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2. J Leucocyte Biol 2007; 82: 1011-1018.
147. Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, Cross A, Roberts CL, McGoldrick A, Edwards SW, Rhodes JM. Microbial mannan inhibits bacterial killing by macrophages: A possible pathogenic mechanism for Crohn's disease. Gastroenterology 2007; 133: 1487-1498.
148. Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-a secretion. Dig Liver Dis 2007; 39: 445-451.
149. Marcus R, Watt J. Seaweeds and ulcerative colitis in laboratory animals. Lancet 1969: 2: 489-490.
150. Marcus AJ, Marcus SN, Marcus R, Watt J. Rapid production of ulcerative disease of the colon in newly-weaned guinea-pigs by degraded carrageenan. J Pharm Pharmacol 1989; 41(6): 42342-42346.
151. Watt J, Marcus R. Experimental ulcerative disease of the colon in animals. Gut 1973; 14: 506-510.
152. Pitcher MCL, Beatty ER, Harris RM, Waring RH, Cummings JH. Sulfur metabolism in ulcerative colitis. Investigation of detoxification enzymes in peripheral blood. Dig Dis Sci 1998; 43: 2080-85.
153. Levitt MD, Furne J, Springfield J, Suarez F, DeMaster E. Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest 1999; 104: 1107-1114.
154. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1996; 36: 897-901.
155. Christl S, Eisner HD, Kasper H, Scheppach W. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig Dis Sci 1996; 41: 2477-2481.
156. Pitcher MCL, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000; 46: 64-72.
157. Dzierzewicz Z, Cwalina B, Weglarz L, Wisniowska B, Szczerba J. Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products. Med Sci Mon 2004; 10: 185-190.
158. Oghe H, Furne J, Springfield J, Rothenberger DA, Madoff RD, Levitt MD. Association between fecal hydrogen sulfide production and pouchitis. Dis Col Rect 2005; 48: 469-475.
159. Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulphatereducing bacteria in gut contents from healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecol 1991; 86: 103-112.
160. Loubinoux J, Bronowicji JP, Pereira IAC, Moungenel JL, Faou AE. Sulfate-reducing bacteria in human feces and their association with inflammatory diseases. FEMS Microbiol Ecol 2002; 40: 107-112.
161. Zinkevich V, Beech IB. Screening of sulfate-reducing bacteria in
162. Gebhart CJ, Barns SM, McOrist S, Lin GF, Lawson GHK. Ileal Symbiont Intracellularis, an obligate intracellular bacterium of porcine intestines showing a relationship to Desulfovibrio species. Int J Syst Bacteriol 1993; 43: 533-538.
163. Fox JG, Dewhirst FE, Fraser GJ, Paster BJ, Shames B, Murphy JC. Intracellular Campylobacter-like organism from ferrets and hamsters with proliferative bowel disease is a Desulfovibrio sp. J Clin Microbiol 1994; 32: 1229-1237.
164. Pitcher MCL. Sulphate-reducing bacteria, sulphur metabolism and ulcerative colitis. MD Thesis, University of Cambridge, 1996.
165. Roediger WEW, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Brit J Exp Pathol 1986; 67: 773-872.
166. Roediger WEW, Duncan A, Kapaniris O, Millard S. Sulphide impairment of substrate oxidation in rat colonocytes: A biochemical basis for ulcerative colitis? Clin Sci 1993; 85: 1-5.
167. Roediger WEW, Duncan A, Kapaniris O, Millard S. Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 1993; 104: 802-809.
168. Babidge W, Millard S, Roediger WEW. Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis. Mol Cell Biochem 1998; 18: 117-124.
169. Stein J, Schroder O, Milovic V, Caspary WF. Mercaptopropionate inhibits butyrate uptake in isolated apical membrane vesicles of the rat distal colon. Gastroenterology 1995; 108: 673-679.
170. Fite A, Macfarlane GT, Cummings JH, Hopkins MJ, Kong SC, Furrie E, Macfarlane S. Identification and quantitation of mucosal and faecal desulfovibrios using real-time PCR Gut 2004; 53: 523-529.
171. Kong SC, Furrie E, Madden J, Kennedy A, Magee E, Macfarlane GT, Cummings JH. Comparison of hydrogen sulphide detoxification enzyme mRNA expression in normal and ulcerative colitis rectal mucosae. Gut 2004; 53(Suppl 3): 142.
172. Kong SC, Furrie E, Macfarlane GT, Cummings JH. Regional variation of mRNA of hydrogen sulphide detoxification enzymes in the colon may predispose to ulcerative colitis. Gut 2005; 54(Suppl 2): 352.
173. Macfarlane S, Cummings JH, Macfarlane GT. Bacterial colonisation of surfaces in the large intestine. In Gibson GR, Roberfroid M, Eds. Colonic Microflora, Nutrition and Health. Pp 71-87. London: Chapman and Hall, 1999.
174. Croucher SC, Houston AP, Bayliss CE, Turner RJ. Bacterial populations associated with different regions of the human colon wall. Appl Environ Microbiol 1983; 45: 1025-1033.
175. Poxton IR, Brown R, Sawyerr A, Ferguson A. Mucosa-associated bacterial flora of the human colon. J Med Microbiol 1997; 46: 85-91.
176. Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemo-taxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis 2004; 38: 1690-1699.
177. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000; 15: 61-68.
178. Ott SJ, Musfeldt M, Wendeoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with inflammatory bowel disease. Gut 2004; 53: 685-693.
179. Sokoi H, Seksik P, Rigottier-Gois I, Lav C, Lepage P, Poddgiaien I, Marteu P, Dore J. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 106-111.
180. Zhang M, Liu B, Zhang Y, Wei H, Lei Y, Zhao L. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J Clin Microbiol 2007; 45: 496-500.
181. Biblioni R, Mangold M, Madsen Kl, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006; 55: 1141-1149.
182. Martinez-Medina M, Aidequer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ. Abnormal microbiota composition in the ileo-colonic mucosa of Crohn's disease patients as revealed by polymeras chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 2006; 12: 136-145.
183. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jamerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550-562.
184. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075.
185. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for the prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621.
186. Blichfeldt P, Blomhoff JP, Mhyre E, Gjone E. Metronidazole in Crohn's disease. Scand J Gastroenterology 1978; 13: 123-127.
187. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15.
188. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-678.
189. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined butesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40.
190. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332.
191. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12: 53-56.
192. Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Barnes P, Lennard-Jones JE. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985; 28: 81-85.
193. Rutgeerts P, Van Assche G, Vermiere S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazol for prophylaxis of postoperative Crohn's disease: a randomized double-blind placebo controlled trial. Gastroenterology 2005; 128: 856-861.
194. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharm Ther 2006; 23: 1117-1125.
195. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997; 54: 679-708.
196. Kolios G, Manousou P, Bourikas L, Notas G, Tsagarakis N, Mouzas I, Koroumalis E. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest 2006; 36: 720-729.
197. Rahimi R, Nikfar S, Rezaie A, Abdollahi A. A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983-1988.
198. Baker DE. Rifaxamin: a nonabsorbable oral antibiotic. Rev Gastroenterol Disord 2005; 5: 19-30.
199. Schultz MG, Rieder HL, Hersh T, Riepe S. Remission of Crohn's disease with antimycobacterial therapy. Lancet 1987; II: 1391-1392.
200. Warren JB, Rees HC, Cox TM. Remission of Crohn's disease with tuberculosis chemotherapy. N Engl J Med 1986; 314: 182.
201. Picciotto A, Gesu GP, Schito GC, Testa R, Varagona G, Celle G. Antimycobacterial therapy in inflammatory bowel disease. Biomed Pharmacother 1989; 43: 141-143.
202. Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25: 203-205.
203. Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, Wilkinson S, Rhodes P, Roberts G, Lawrie BW, Evans KT, Jenkins PA, Williams GT, Strohmeyer G, Kreuzpainter G, Thomas GAO, Calcraft B, Davies PS, Morris TJ, Morris J. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35: 363-368.
204. Thomas GA, Swift GL, Green JT, Newcombe RG, Braniff-Mathews C, Rhodes J, Wilkinson S, Strohmeyer G, Kreuzpainter G. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut 1998; 42: 497-500.
205. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518.
206. Goodgame RW, Kimball K, Akram S, Ike E, Ou CN, Sutton F, Graham D. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Therap 2001; 15: 1861-1866.
207. Graham DY Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995; 108: A826.
208. Afdhal NH, Long A, Lennon J, Crowe J, O' Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991; 36: 449-453.
209. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Sci 2002; 34: 22-28.
210. Basilisco G, Ranzi T, Campanini C, Piodi L, Bianchi PA. Controlled trial of rifabutin in Crohn's disease. Curr Ther Res 1989; 46: 242-250.
211. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-729.
212. Bernstein LH, Frank MS, Brandt IJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 357-365.
213. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow up study. Gastroenterology 1982; 83: 383-387.
214. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001; 135: 906-918.
215. Duffy LF, Daum F, Fisher SE, Selman J, Vishnubhakat SM, Aiges HW, Markowitz JF, Silverberg M. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88: 681-684.
216. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-1212.
217. Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 1989; 11: 392-395.
218. Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, Fireman Z. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 1987; 9: 415-417.
219. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46.
220. Ohkusa T, Nomura T, Terai T, Miwa H, Kobavashi O, Hoio M, Takei Y, Ogihara T, Hirai S, Okavusa I, Sato N. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005; 11: 1334-1342.
221. Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N. Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther 2005; 21: 1017-1027.
222. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078.
223. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G. A prospective randomised controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-974.
224. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou, G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454-456.
225. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin in adjunctive treatment in acute exacerbation of idiopathic colitis. Gut 1985; 26: 1380-1384.
226. Burke DA, Axon TR, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990; 4: 123-129.
227. Lobo A, Burke, DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993; 7: 155-158.
228. Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, Malagelada JR. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 1998; 4: 1-5.
229. Gionchetti P, Rizzello E, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-1221.
230. Pinto A, Borruto G, Dell'Anna A, Turco L, Ferrieri A. An open, uncontrolled trial of oral rifaximin, an non-absorbable antibiotic in inflammatory bowel disease refractory to conventional therapy. Eur J Clin Res 1997; 9: 217-224.
231. Ohkusa T, Okayasu I, Ogihara T, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79-83.
232. Rizzello F, Gionchetti P, Venturi A, Ferretti M, Peruzzo S, Raspanti X, Picard M, Canova N, Palazzini E, Campieri M. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1987; 54: 91-93.
233. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44: 2205-2206.
234. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73: 13-27.
235. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52: 2920-2925.
236. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis J Chemother 2002; 14: 290-295.
237. Guslandi M, Mezzi G, Sorgi M, Testoni PA. Saccharomyces boulardii in maintenance treatment in Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464.
238. Van Gossum A, Dewit O, Louis E, de Hergtogh G, Baert F, Fontaine F, Devos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-142.
239. Marteau P, Lehman M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soule JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Arbitol V, Blum-Sperisen S, Mary JY. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence of Crohn's disease: a randomised, double-blind, placebo controlled GETAID trial. Gut 2006; 55: 842-847.
240. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemer M, Rosh JR, Tola V, Zholudev A, Vanderhoof JA, Hibberd PL. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-839.
241. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5.
242. Zocco MA, Zileri Dal Verne L, Armuzzi A, Nista EC, Papa A, Candelli M. Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology 2003; 124 (4 Suppl 1): A201.
243. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection in Crohn's disease: a randomised controlled with Lactobacillus GG. Gut 2002; 51: 405-409.
244. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453-457.
245. Campieri M, Rizzello F, Venturi A, Poggili G, Ugolini F, Helwig U. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study versus mezalamine. Gastroenterology 2000; 118 (4 Suppl 2): A781.
246. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-658.
247. Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40: 137-145.
248. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall. Probiotics for maintenance of remission in Crohn's disease (Review). The Cochrane Collaboration Issue 1. Pp 1-21. Wiley, 2007.
249. Borruel N, Carol M, Cassellas F, Antolin M, Espin E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51: 659-664.
250. Kruis W, Schuta E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858.
251. Rembracken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639.
252. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623.
253. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698.
254. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574.
255. Shanahan F, Guarner F, von Wright A, Vilpponene-Salmela T, O'Donoghue D, Kiely B. A one year, randomised, double-blind, placebo controlled trial of a lactobacillus or a bifidobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006; 130(S2): A44.
256. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH, Dan HL, Jian YT, Chen XQ. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10: 1521-1525.
257. Biblioni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546.
258. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigandi P, Matteuzzi D, Campieri M. Impact on the composition of the fecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108.
259. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141.
260. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomised controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
261. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-47.
262. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
263. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigandi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209.
264. Lammers KM, Vergopoulos A, Babel N, Gionchetti P, Rizzello F, Morselli C, Caramelli E, Fiorentino M, d'Errico A, Volk HD, Campieri M. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis 2005; 11: 447-454.
265. Mimura T, Rizzullo F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114.
266. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22: 721-728.
267. Ulisse S, Gionchetti P, D'Alò S, Paola Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001; 96: 2691-2699.
268. Kuisma W, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17: 509-515.
269. Gosselinks MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47: 876-884.
270. Laake KO, Line PD, Grzyb K, Aamodt G, Aabakken L, Roset A, Hvinden AB, Bakka A, Eide J, Bjorneklett A, Vatn MH. Assessment of mucosal inflammation and blood flow in response to four weeks intervention with probiotics in patients operated with a J-configured ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol 2004; 39: 1228-1235.
271. Furrie E, Macfarlane S, Kennedy A, Cummings H, Walsh SV, O'Neil DA, Macfarlane GT. Synbiotic therapy significantly reduces molecular markers of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut 2005; 54: 242-249.
272. Welters CF, Heinema E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with ileal pouch-anal anastomosis. Dig Colon Rect 2002; 45: 621-627.
273. Hussey TA, Issenman RM, Persad R, Olley AR, Christensen BA. Nutrition therapy in pediatric Crohn's disease patients improves nutrition status and decreases inflammation. J Pediatr Gastroenterol 2003; 37: A341.
274. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A. Clinical, microbiological and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55: 348-355.
275. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 2007; 52: 385-389.